1986

• Aurobindo Pharma Limited (APL) one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company by Mr. P.V.Ramprasad Reddy and Mr. K.Nityananda Reddy.

1988

• Started operations with a single manufacturing unit semi synthetic penicillins (SSPs) at Pondicherry.

1992

• Commenced API Exports

1994-95

• Initial Public Offering Started formulations production.
• Aurobindo Pharma became a public company in 1995.

1999-2000

• Diversified product portfolio further with the introduction of wide range of Cephalosporins (Oral & Sterile) and anti - virals in addition to macrolides, anti-ulcerants, quinolones, semi-synthetic penicillins, and formulations for domestic and export market.
• Joint Ventures launched for formulations business in US.

2004-05

• The State Labour Department of the Government of Andhra Pradesh awarded Aurobindo the 'Best Management Award' in 2005 for the Company's contributions towards community development, harmonious employee relations and employee welfare.
• US FDA unit of US Department of Health and Human Science approved the company's Unit VIII facility and received US FDA clearance for AIDS drugs.

2005-2006

• Aurobindo made a strategic entry into the premium markets of USA & Europe with generic formulations, participating in the PEPFAR program initiated by the Government of USA.
  APL acquired UK based Milpharm Limited, engaged in marketing generic formulations in the UK market.

2007-08

• Acquired formulations facility in US (AuroLife) and in Netherlands (Pharmacin).
• Aurobindo Pharma unveiled a new Logo and Corporate Identity at a ceremony in Hyderabad. The new corporate logo reflects the company's pace of innovation and its industry leadership.

2010

• Commenced operations of SEZ Unit VII and AuroLife, US facilities.

2012

• First approval of controlled substance formulations in the US.
• Set up Auro Peptide to foray into peptides.

2013

• Acquired Silicon Lifesciences for building presence in Penems.
• Commenced marketing specialty injectables in the US through Auromedics.

2014

• Acquired commercial operations from Actavis in Europe.

2016

• Entered Biosimilars and Vaccines segment.
• Filed first peptide DMF.

2017-18

• Acquired Generis in Portugal - Focus on differentiated technology platforms and Specialty Pharmaceuticals.
• Commissioned fully-automated distribution center in the US.

2019-20

• Acquired Apotex's businesses in 5 European countries.
• Acquired portfolio of 7 marketed branded oncology injectables from Spectrum Pharma Inc.
• Started clinical trials for the first biosimilar.
• Started setting up manufacturing facility at Taizhou, China.
• Filed first Metered Dose Inhaler (MDI) and Received approval for first Nasal product In the US.
• Turned into a net cash company.

2021

• Started Phase III clinical trials for PCV.
• Acquired 9 OTC brands.
• Filed the first biosimilar with the European Medical Agency (EMA).

2022

• Entered domestic market by acquiring Veritaz Healthcare Ltd.
• Acquired 51% stake in Hyderabad based oncology player GLS Pharma.

2023

• Announced acquisition of the branded portfolio of Viatris/Pfizer in Indonesia.

2024

• Acquisition of remaining stake in GLS Pharma.
• Inauguration of Lyfius Pharma by Honorable PM Narendra Modi Ji
• EU GMP approval to CuraTeQ.